Literature DB >> 17253935

Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer.

Ying Chen1, Amanda E Toland, Jane McLennan, Jane Fridlyand, Beth Crawford, Joseph F Costello, John L Ziegler.   

Abstract

Hereditary breast cancer accounts for about 10% of breast cancer in the United States, but high-penetrance, germ-line mutations in BRCA1 and BRCA2 are responsible for less than half of these high-risk families. Epigenetic modification of DNA by promoter methylation can result in a potentially heritable epimutation that silences the gene. Using a highly sensitive technique, we assayed the BRCA1 gene for promoter methylation among 41 BRCA1- and BRCA2-negative women whose personal and family histories indicated a high risk of BRCA mutations (median prior likelihood = 60%) using the BRCAPro model. DNA from 19 women who were "true negatives" for BRCA mutations served as controls. We found no evidence for promoter methylation among the high-risk women who tested negative for germ-line BRCA mutations. Thus, epimutation is an unlikely explanation for hereditary breast cancer in women who test negative for BRCA mutations.

Entities:  

Mesh:

Year:  2006        PMID: 17253935     DOI: 10.1089/gte.2006.10.281

Source DB:  PubMed          Journal:  Genet Test        ISSN: 1090-6576


  7 in total

1.  Methylation profiles of the BRCA1 promoter in hereditary and sporadic breast cancer among Han Chinese.

Authors:  Da Pang; Yashuang Zhao; Weinan Xue; Ming Shan; Yanbo Chen; Youxue Zhang; Guoqiang Zhang; Feng Liu; Dalin Li; Yanmei Yang
Journal:  Med Oncol       Date:  2011-11-11       Impact factor: 3.064

2.  Germline promoter hypermethylation in BRCA1 and BRCA2 genes is not present in hereditary breast cancer patients.

Authors:  M Rodríguez-Balada; B Roig; M Melé; M Salvat; L Martorell; J Borràs; J Gumà
Journal:  Clin Transl Oncol       Date:  2018-02-05       Impact factor: 3.405

3.  Absence of germline mono-allelic promoter hypermethylation of the CDH1 gene in gastric cancer patients.

Authors:  Hidetaka Yamada; Kazuya Shinmura; Masanori Goto; Moriya Iwaizumi; Hiroyuki Konno; Hideki Kataoka; Masami Yamada; Takachika Ozawa; Toshihiro Tsuneyoshi; Fumihiko Tanioka; Haruhiko Sugimura
Journal:  Mol Cancer       Date:  2009-08-12       Impact factor: 27.401

4.  Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer.

Authors:  Tamara Hansmann; Galyna Pliushch; Monika Leubner; Patricia Kroll; Daniela Endt; Andrea Gehrig; Sabine Preisler-Adams; Peter Wieacker; Thomas Haaf
Journal:  Hum Mol Genet       Date:  2012-07-27       Impact factor: 6.150

5.  BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype.

Authors:  Cameron Snell; Michael Krypuy; Ee Ming Wong; Maurice B Loughrey; Alexander Dobrovic
Journal:  Breast Cancer Res       Date:  2008-02-12       Impact factor: 6.466

6.  Programmed genetic instability: a tumor-permissive mechanism for maintaining the evolvability of higher species through methylation-dependent mutation of DNA repair genes in the male germ line.

Authors:  Yongzhong Zhao; Richard J Epstein
Journal:  Mol Biol Evol       Date:  2008-06-04       Impact factor: 16.240

Review 7.  Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer.

Authors:  Ee Ming Wong; Melissa C Southey; Mary Beth Terry
Journal:  Br J Cancer       Date:  2020-02-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.